Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we ...

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) entered into oversold territory, hitting an RSI reading of 28 ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently discussed. In a recent episode of CNBC’s Squawk On The ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with ... treatment that could still show differentiation in type 2 diabetes. UBS is a buyer of weakness and says shares are at an ...

Novo Nordisk is doubling down on its collaboration ... focus to cover Novo’s defining indications—obesity and Type 2 diabetes—and increases the program cap to 20. If the programs hit their ...

Novo Nordisk provided significant funding to UK pharmacies for training, advertising and patient resources ... Compounding For Its Early-Generation Diabetes Drug Between 2021 and 2023, Novo ...